|
Video: What is a Stock Split?
|
|
Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism. According to our Cerevel Therapeutics Holdings stock split history records, Cerevel Therapeutics Holdings has had 1 split. | |
|
Cerevel Therapeutics Holdings (CERE) has 1 split in our Cerevel Therapeutics Holdings stock split history database. The split for CERE took place on April 09, 2015. This was a 1 for 8 reverse split, meaning for each 8 shares of CERE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.
When a company such as Cerevel Therapeutics Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Cerevel Therapeutics Holdings stock split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cerevel Therapeutics Holdings shares, starting with a $10,000 purchase of CERE, presented on a split-history-adjusted basis factoring in the complete Cerevel Therapeutics Holdings stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/31/2020 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$11.20 |
|
End price/share: |
$42.38 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
278.39% |
|
Average Annual Total Return: |
43.88% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$37,834.85 |
|
Years: |
3.66 |
|
|
|
Date |
Ratio |
04/09/2015 | 1 for 8 |
|
|